Evidence for numerous therapies with antithrombotic, immunomodulatory, and anti-inflammatory properties in COVID-19 continues to rapidly evolve2. While we do not expect clinical trial data on routine thromboprophylaxis use in the outpatient setting to be released quite soon, current available data suggests the need for randomized trials that address the putative benefits of thromboprophylaxis in selected, high risk categories of COVID-19 outpatients, who may benefit from lowering their likelihood of developing pulmonary and systemic thrombosis. However, given the low risk of venous thromboembolism in this setting, routine pre-hospital thromboprophylaxis seems to remain unwarranted as yet. Vaccination remains the best intervention for reliable protection and preventing severe disease, hospitalization, and death.
Thromboprophylaxis in outpatients with COVID-19: a safe bet or tilting at windmills?
Lippi, Giuseppe;
2022-01-01
Abstract
Evidence for numerous therapies with antithrombotic, immunomodulatory, and anti-inflammatory properties in COVID-19 continues to rapidly evolve2. While we do not expect clinical trial data on routine thromboprophylaxis use in the outpatient setting to be released quite soon, current available data suggests the need for randomized trials that address the putative benefits of thromboprophylaxis in selected, high risk categories of COVID-19 outpatients, who may benefit from lowering their likelihood of developing pulmonary and systemic thrombosis. However, given the low risk of venous thromboembolism in this setting, routine pre-hospital thromboprophylaxis seems to remain unwarranted as yet. Vaccination remains the best intervention for reliable protection and preventing severe disease, hospitalization, and death.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
